Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Sequent Scientific
Mid Cap•1,195 Employees•IPO 2016
Current Price
₹201.17
7.19 (3.71%)Updated
Today's Range
195
₹201.17
202
52 Week Range
52W Low₹117.35
52W High₹257.85
₹201.17
Downside71.43%
Upside28.18%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹5,067.01 Cr
Market Cap
Total market value of companyP/E Ratio
170.73
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
4.65
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹1.15
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
1.72%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
8.47%
ROCE
Return on Capital Employed. >15% is goodNet Margin
1.85%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-21.44%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
5.64%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
13.10%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
127.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.68
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹28.15
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
52.30%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Strong promoter holding (52.3%) indicates high insider confidence and stability.
- •Impressive quarterly profit growth (127%) signals strong recent earnings momentum.
Weaknesses
5 points- •Elevated P/E ratio (196.26) suggests potential overvaluation compared to peers.
- •Low Return on Equity (1.72%) indicates inefficient capital utilization.
Opportunities
4 points- •Growing pharmaceutical sector driven by increasing healthcare demand.
- •Rising DII holdings (12.91%) signal increasing institutional investor confidence.
Threats
5 points- •Intense competition from larger pharmaceutical players pressures market share.
- •Stringent regulatory changes and approvals pose risks to operations.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹217.78 | +₹16.61 | +8.26% |
| R3 | ₹210.78 | +₹9.61 | +4.78% |
| R2 | ₹206.39 | +₹5.22 | +2.59% |
| R1 | ₹203.78 | +₹2.61 | +1.30% |
| PIVOT | ₹199.39 | -1.78 | -0.88% |
| CURRENT | ₹201.17 | - | - |
| S1 | ₹182.78 | -₹18.39 | -9.14% |
| S2 | ₹189.78 | -₹11.39 | -5.66% |
| S3 | ₹192.39 | -₹8.78 | -4.36% |
| S4 | ₹196.78 | -₹4.39 | -2.18% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-43.4% vs avg
3.64L
(22 Jan 2026)Delivery %-0.6% vs avg
47.0%
(22 Jan 2026)Avg Volume (20D)20-day average
6.43L
(24 Dec - 22 Jan)Avg Delivery %Trend ↓
47.5%
(24 Dec - 22 Jan)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Shilpa Medicare Ltd
234.00 %
Highest Dividend Yield
RPG Life Sciences Ltd
1.22 %
Peer Comparison
| Company Name |
|---|
 Aarti Drugs Ltd |
 Aarti Pharmalabs Ltd |
 FDC Ltd |
 Marksans Pharma Ltd |
 Orchid Pharma Ltd |
 RPG Life Sciences Ltd |
 Shilpa Medicare Ltd |
 Sun Pharma Advanced Research Company Ltd |
 Sun Pharmaceutical Industries Ltd |
 Supriya Lifescience Ltd |
 Zota Health Care Ltd |
About
Sequent Scientific Ltd
Sequent Scientific Limited is a global veterinary healthcare company with a significant presence in Europe and Asia. Its core business revolves around the development, manufacturing, and distribution of animal health products. This includes a wide range of active pharmaceutical ingredients (APIs) and formulated medications targeting various animal health needs.
The company's product portfolio is diverse, encompassing several key therapeutic areas. This includes anthelmintics (for internal and external parasites), anti-protozoal medications, nutraceuticals (supplements promoting animal health), nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives, and dermatological treatments. This breadth of offerings allows Sequent to cater to a comprehensive range of animal health challenges.
Beyond its core pharmaceutical business, Sequent also provides crucial analytical services to support various industries. These services are particularly valuable to companies in the API, pharmaceutical, personal care, and nutraceutical sectors. The analytical solutions encompass method validation, stability testing, and microbiology testing for both APIs and finished products. This adds another layer of revenue and strengthens its position within the scientific community.
Sequent Scientific Limited's history stretches back to 1985, originally operating under the name PI Drugs & Pharmaceuticals Ltd. The company underwent a name change in 2009 and is currently headquartered in Mumbai, India. It operates internationally, serving markets across Europe and Asia, highlighting its global reach and ambition within the veterinary pharmaceutical industry. Currently, it is a subsidiary of CA Harbor Investments.
COMPANY FACTS - SEQUENT
Registered Address
301/A, 3rd Floor, Dosti Pinnacle,, Plot No.E7,Road No. 22,, Wagle Industrial Area, Thane (W),
Mumbai
MAHARASHTRA
IN
Tel: 912241114777
Website:https://sequent.in/
Investor Relations:http://www.sequent.in/investor-relations.aspx
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,195
IPO Date: 10/03/2016
MANAGEMENT - SEQUENT
Dr. Kamal Sharma
Independent Non-Executive Chairman of the Board
Mr. Rajaram Narayanan
Chief Executive Officer, Managing Director, Executive Director
Mr. Saurav Bhala
Chief Financial Officer
Ms. Yoshita Vora
Company Secretary and Compliance Officer
Mr. Prasad Lad
Vice President - Human Resources and Admin
Mr. Pankaj Lohan
Vice President, Head - India Formulations
Mr. Vedprakash Ragate
Executive Director
Mr. Yawar Abbas
Emerging Markets
Mr. Alexis Goux
Global Formulations
Mr. Ashish Kakabalia
Business Development and Research & Development
Mr. Alan Kelly
United States Operations
Mr. Murat Mentes
Turkey Operations
Investor Questions Answered
Sequent Scientific Ltd (SEQUENT) Stock FAQs
Get answers to the most common questions about Sequent Scientific Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Sequent Scientific Ltd (SEQUENT) is ₹201.17. Today, the stock has gained by ₹7.19 (3.71%), trading in a range of ₹195 to ₹202. The stock opened at ₹195 with a trading volume of 3,64,240 shares.
Sequent Scientific Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹5,067.01 crores, P/E ratio of 170.73, ROE of 1.72%, and ROCE of 8.47%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Sequent Scientific Ltd (SEQUENT) is ₹257.85, while the 52-week low is ₹117.35. Currently trading at ₹201.17, the stock is 59.7% away from its 52-week low and 22.0% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Sequent Scientific Ltd stock at ₹201.17 depends on multiple factors. The stock is currently trading with a P/E ratio of 170.73 and P/B ratio of N/A. Today's performance shows a gain of 3.71%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Sequent Scientific Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹201.17, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Sequent Scientific Ltd's key financial metrics include: P/E Ratio: 170.73, P/B Ratio: N/A, ROE: 1.72%, ROCE: 8.47%, Dividend Yield: 0.00%, EPS: ₹1.15, Book Value: ₹28.15, Debt-to-Equity: 0.68, and Current Ratio: N/A. The company's market cap stands at ₹5,067.01 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Sequent Scientific Ltd stock opened at ₹195 and is currently trading at ₹201.17, showing a gain of ₹7.19 (3.71%). The intraday high is ₹202 and low is ₹195. The trading volume stands at 3,64,240 shares, indicating moderate market participation today.
Sequent Scientific Ltd has a Price-to-Earnings (P/E) ratio of 170.73, which means investors are willing to pay ₹170.73 for every ₹1 of earnings. With an EPS of ₹1.15, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Sequent Scientific Ltd has a market capitalization of ₹5,067.01 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹201.17) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Sequent Scientific Ltd has a book value of ₹28.15 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹201.17, which is 614.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Sequent Scientific Ltd has a Return on Equity (ROE) of 1.72% and Return on Capital Employed (ROCE) of 8.47%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Sequent Scientific Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Sequent Scientific Ltd has a debt-to-equity ratio of 0.68, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Sequent Scientific Ltd has an Earnings Per Share (EPS) of ₹1.15, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹201.17 and P/E ratio of 170.73, investors are paying 170.73 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Sequent Scientific Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Sequent Scientific Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Sequent Scientific Ltd stock, consider: 1) Fundamental Analysis - Review P/E (170.73), ROE (1.72%), debt-to-equity (0.68), and growth rates. 2) Technical Analysis - Check 52-week range (₹117.35 - ₹257.85), moving averages, and chart patterns. 3) Valuation - Compare current price (₹201.17) with book value (₹28.15) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Sequent Scientific Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹201.17 is 9959x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Sequent Scientific Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹117.35 - ₹257.85). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.68 indicates leverage. 4) Liquidity Risk - Based on trading volume of 3,64,240 shares. 5) Valuation Risk - P/E of 170.73 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Sequent Scientific Ltd operates in the industry with key metrics: P/E ratio of 170.73, ROE of 1.72%, market cap of ₹5,067.01 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.68), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Sequent Scientific Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹201.17, with a 52-week range of ₹117.35 to ₹257.85. Based on fundamentals like P/E (170.73), ROE (1.72%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Sequent Scientific Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹201.17. 2) Fundamental Deterioration - Declining ROE (currently 1.72%), increasing debt (D/E: 0.68), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Sequent Scientific Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu